Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Volution, Nexteq

(Sharecast News) - Over at Berenberg, analysts hiked their target price on ventilation equipment business Volution to 600.0p from 500.0p on Wednesday following the group's full-year trading update. Berenberg stated that while the macro backdrop has "remained challenging" given subdued levels of new construction activity, high interest rates and weak consumer confidence, Volution has continued to be "resilient", with management confident about the brands and strategy.

Overall revenue for FY24 was up by 7% year-on-year in constant currency terms, of which slightly over 1% was organic growth.

As the German bank flagged back in March, key focus points were the strength of the outperformance in Volution's UK residential division, a resilient performance in Europe given the market weakness, further delivery of strong adjusted underlying earnings margins, and very clean cash conversion that leaves the business at 0.5x EBITDA pre-leases and well positioned for future consolidation.

"With the company guiding to a 'slight' increase in adjusted earnings per share versus prevailing consensus expectations, we increase our FY24 numbers by circa 1.5%," said Berenberg, which has a 'buy' rating on the stock.

"As such, with Volution shares also performing well and recently breaking through our prevailing 500,0p price target, we have increased our price target to 600.0p to reflect this change in peer multiples, and our ongoing confidence both in the company's strategy and its ability to participate in the expected recovery in end-market demand."

Analysts at Canaccord Genuity lowered their target price on B2B technology group Nexteq from 300.0p to 200.0p on Wednesday despite "strong margins and cash", noting that destocking persisted.

Canaccord said revenue for H124 was expected to be $48.2m, down 15% year-on-year, reflecting soft demand across both its Quixant and Densitron offerings as a result of persistent destocking, in line with wider industry trends.

The Canadian bank also said the impact has been amplified by some larger customers deciding to delay planned product launches and instead sweat assets for longer given a challenging macro backdrop.

"We have updated our model to reflect the new guidance. This sees our FY24E adjusted pre-tax profit reduce by 36% to $9.6m. We now see net cash 7% better at $38.0m. For FY25, the timing of planned customer spending remains uncertain at present, but we expect strong margins and a continued focus on cost management to at least maintain profit levels. We reduce FY25E adjusted PBT by 42% to $9.7m as a result," said Canaccord, which has a 'buy' rating on the stock.

"On our revised estimates, Nexteq trades on a P/E of 13.9x for 2024E falling to 13.7x for 2025E. P/E ex cash is 8.6x/8.0x respectively with net cash representing ~38% of current market capitalisation. That looks too cheap for us given the strength of gross margins and underlying cash generation, while absolute profit levels are likely to rebuild quickly, in our view, as cyclical destocking trends ease."

Share this article

Related Sharecast Articles

Broker tips: Ascential, CAB Payments
(Sharecast News) - Analysts at Berenberg upgraded business-to-business media firm Ascential to 'buy' from 'hold' and hiked their target price on the stock to 568.0p from 395.0p following a takeover offer from Informa.
Broker tips: SThree, Compass Group
(Sharecast News) - Analysts at Berenberg lowered their target price on specialist staffing organisation SThree from 550.0p to 520.0p on Tuesday but said the group's contract focus offered resilience versus peers.
Broker tips: The Gym Group, MP Evans
(Sharecast News) - Analysts at Berenberg upgraded their stance on The Gym Group from 'hold' to 'buy' on Monday and hiked their target price on the stock from 121.0p to 180.0p, stating the company was "in good shape".

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.